Cargando…

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers. Patients received cetu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, S-W, Oh, D-Y, Im, S-A, Park, S R, Lee, K-W, Song, H S, Lee, N-S, Lee, K H, Choi, I S, Lee, M H, Kim, M A, Kim, W H, Bang, Y-J, Kim, T-Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634707/ https://www.ncbi.nlm.nih.gov/pubmed/19127259 http://dx.doi.org/10.1038/sj.bjc.6604861

Ejemplares similares

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
por: Yoo, C, et al.
Publicado: (2009)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
por: Lee, Dong Hyun, et al.
Publicado: (2011)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
por: De Vita, F, et al.
Publicado: (2011)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
por: Kim, J-S, et al.
Publicado: (2009)

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
por: Kang, H J, et al.
Publicado: (2008)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Serum biomarker panels for the diagnosis of gastric adenocarcinoma
por: Ahn, H S, et al.
Publicado: (2012)

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
por: Baek, J H, et al.
Publicado: (2006)

Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer
por: Jo, J-C, et al.
Publicado: (2012)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
por: Lee, J-L, et al.
Publicado: (2008)

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
por: Okamoto, W., et al.
Publicado: (2022)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
por: Oki, Eiji, et al.
Publicado: (2019)

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
por: An, E., et al.
Publicado: (2017)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Gastric lymphangioma.
por: Kim, H. S., et al.
Publicado: (2001)

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
por: Wainberg, Z A, et al.
Publicado: (2011)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
por: Lee, H E, et al.
Publicado: (2012)

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
por: Conroy, T, et al.
Publicado: (2010)

A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer
por: Wang, Xiang, et al.
Publicado: (2016)

High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer
por: Kim, D-W, et al.
Publicado: (2008)

Combination chemotherapy of oral 5'-deoxy-5-fluorouridine and cisplatin in advanced gastric cancer: a phase II study.
por: Ahn, M. J., et al.
Publicado: (1998)

A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
por: Oh, S C, et al.
Publicado: (2007)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial
por: Karoui, Mehdi, et al.
Publicado: (2015)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Intrapulmonary and gastric teratoma : report of two cases.
por: Joo, M., et al.
Publicado: (1999)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020)

Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells
por: Jeon, T-Y, et al.
Publicado: (2010)

Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
por: Lee, H E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_6mt0padn9c8h54vgcephr5foe7